Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Sales and Divestitures (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $34762.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Gains from Sales and Divestitures changed N/A year-over-year to $34762.0, compared with a TTM value of $34762.0 through Sep 2023, changed N/A, and an annual FY2021 reading of $71429.0, down 14.28% over the prior year.
  • Gains from Sales and Divestitures was $34762.0 for Q3 2023 at Terns Pharmaceuticals, up from $27055.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $83333.0 in Q4 2020 and bottomed at $27055.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 3 years is $59906.2, with a median of $71429.0 recorded in 2021.
  • Peak annual rise in Gains from Sales and Divestitures hit 14.28% in 2021, while the deepest fall reached 14.28% in 2021.
  • Year by year, Gains from Sales and Divestitures stood at $83333.0 in 2020, then fell by 14.28% to $71429.0 in 2021, then crashed by 51.33% to $34762.0 in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for TERN at $34762.0 in Q3 2023, $27055.0 in Q2 2023, and $71429.0 in Q4 2021.